Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea

Yoonjung Kim, Bitna-Ha, Shin-Woo Kim, Hyun-Ha Chang, Ki Tae Kwon, Sohyun Bae and Soyoon Hwang

Abstract
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues to progress, awareness about its long-term impacts has been growing. To date, studies on the long-term course of symptoms, factors associated with persistent symptoms, and quality of life after 12 months since recovery from acute COVID-19 have been limited.

Methods: A prospective online survey (First: September 8, 2020–September 10, 2020; Second: May 26, 2021–June 1, 2021) was conducted on recovered patients who were previously diagnosed with COVID-19 between February 13, 2020 and March 13, 2020 at Kyungpook National University Hospital. Responders aged between 17 and 70 years were included in the study. Overall, 900 and 241 responders were followed up at 6 and 12 months after recovery from COVID-19 in the first and second surveys, respectively. Clinical characteristics, self-reported persistent symptoms, and EuroQol-5-dimension (EQ5D) index score were investigated for evaluating quality of life.

Results: The median period from the date of the first symptom onset or COVID-19 diagnosis to the time of the survey was 454 (Interquartile range [IQR] 451–458) days. The median age of the responders was 37 (IQR 26.0–51.0) years, and 164 (68.0%) responders were women. Altogether, 11 (4.6%) responders were asymptomatic, and 194 (80.5%), 30 (12.4%), and 6 (2.5%) responders had mild, moderate, and severe illness, respectively. Overall, 127 (52.7%) responders still experienced COVID-19-related persistent symptoms and 12 (5.0%) were receiving outpatient treatment for such symptoms. The main symptoms were difficulty in concentration, cognitive dysfunction, amnesia, depression, fatigue, and anxiety. Considering the EQSD index scores, only 59.3% of the responders did not have anxiety or depression. Older age, female sex, and disease severity were identified as risk factors for persistent neuropsychiatric symptoms.

Conclusion: COVID-19-related persistent symptoms improved over time; however, neurological symptoms can last longer than other symptoms. Continuous careful observation of symptom improvement and multidisciplinary integrated research on recovered COVID-19 patients are required.

Keywords: COVID-19, SARS-CoV-2, Sequelae, Persistent symptoms, Long COVID, Quality of life
symptoms are chronic fatigue, anosmia, ageusia, general neurological deterioration, and dyspnea [1–4]. At present, why long-term persistent symptoms are identified in recovered COVID-19 patients is unclear. However, most researchers and clinicians hypothesize that the long-term persistent symptoms after recovery from COVID-19 are associated with the ability of SARS-CoV-2 to trigger a massive inflammatory response [1]. Persistent symptoms are often associated with the severity of symptoms during the acute illness phase; however, long-lasting symptoms can also occur following mild illness and across all ages [5, 6]. Among the persistent symptoms, a key concern is the neurological complications of COVID-19 [7]. The impact of SARS-CoV-2 infection can have long-term negative impacts on cognitive functions, daily functioning, and quality of life [8–10]. A large proportion of patients experience persistent cognitive problems with memory loss and impaired ability to concentrate for several months after their recovery from COVID-19 [11]. Cognitive impairments were the most pronounced in people who had been hospitalized. Most importantly, cognitive impairments were also observed in non-hospitalized patients who were no longer reporting symptoms [12]. Until now, the risk factors associated with major neurological persistent symptoms that last more than 12 months are not yet known. Furthermore, to the best of our knowledge, studies on persistent symptoms and long-term consequences of COVID-19 on health-related quality of life and functional status after 12 months of recovery from an acute COVID-19 infection are limited [2, 3, 13]. Daegu was the first city where a severe COVID-19 outbreak affected more than 5000 individuals in early 2020 in Korea, thereby making it a suitable place for the investigation of the long-term COVID-19-related persistent symptoms. Therefore, we investigated the persistent symptoms in recovered patients in Daegu city to identify such symptoms prevalent 12 months after COVID-19 infection, factors associated with the major neurological persistent symptoms, and the long-term impact of COVID-19 on the quality of life in recovered COVID-19 patients.

Methods
Study design and population
This prospective online survey was conducted two times by infectious disease physicians at the Kyungpook National University Hospital located in Daegu city. The first survey period was from September 8, 2020 to September 10, 2020. In total, 5252 patients with COVID-19 (age 16–70 years) confirmed through polymerase chain reaction in Daegu city were identified from the clinical data registry provided by the Daegu Center for Infectious Diseases Control and Prevention and all included patients had in-hospital care or care in facility isolation centers. The date of diagnosis of the COVID-19 patients enrolled in the first survey was between February 18, 2020 and March 14, 2020. Among the 5252 patients in the first survey, 900 subjects were followed up for the initial 6 months after COVID-19 symptom onset or diagnosis. The first survey response rate was 17.1% (900 out of 5252). The second survey followed up after 12 months from acute COVID-19 infection was conducted from May 26, 2021 to June 1, 2021. A total of 7201 patients diagnosed with COVID-19 between February 17, 2020 and February 25, 2021 were identified from the clinical data registry provided by the Daegu Center for Infectious Diseases Control and Prevention. To distinguish and match responders in the first online survey with those in the second online survey, sex, birth year and date, and last four digit numbers of cellular phone were used.

The individualized questionnaire list included sex, birth year, birth date, residential address, COVID-19 diagnosis date, quarantine end date, symptoms identified during or after acute COVID-19 infection, oxygen treatment history, admission place during acute COVID-19, an open text field to add other persistent symptoms, newly diagnosed diseases after COVID-19, exacerbation of underlying diseases after COVID-19, and outpatient treatment history for COVID-19-related persistent symptoms or signs. Clinical data of the respondents in terms of COVID-19 diagnosis date, first symptom onset date, and disease severity were provided by the registry of Daegu Center for Infectious Diseases Control and Prevention. All data were reviewed by infectious disease physicians. EuroQol-5 dimension (EQ5D) index score was used to assess the quality of life associated with COVID-19-related persistent symptoms. EQ5D index score was classified into five categories as follows: Mobility, self-care, usual activities (e.g., work, study, housework, family, or leisure activities), Pain/Discomfort, and Anxiety/Depression.

All respondents in the study were diagnosed with SARS-CoV-2 infection via real-time reverse transcription polymerase chain reaction assay using nasopharyngeal swabs or other upper respiratory tract specimens. Respondents were considered recovered if they were no longer experiencing symptoms at the time of completion of the survey. End of quarantine period was defined as having two consecutive negative PCR results within a 24-h interval.

Severity scores during acute COVID-19 infection were classified as follows: (1) asymptomatic: no symptoms or discomfort throughout the entire disease period, with body temperature < 37.5 °C; (2) mild: presence of symptoms with or without fever (≥ 37.5 °C), but not manifesting or identified pneumonia; (3) moderate: pneumonia...
provided digital informed consents before the questionnaire was administered. Without the informed consent, the remaining questionnaire could not be completed. All the study protocols were in accordance with relevant guidelines and regulations.

Results
Demographics and characteristics
The survey response rate was 9.4% (678 out of 7201 respondents). Of the total of 678 responders, 241 responders diagnosed with COVID-19 between February 18, 2020 and March 13, 2020 participated in the first online survey. The median days taken from the diagnosis of COVID-19 to the investigation period were 454 days [IQR 451.0; 458.0]. The total number of women was 164 (68.0%). The median age was 37.0 years [IQR 26.0; 51.0]. In addition to participants aged 60–70 years (n=20, 8.3%), most of the participants (n=99, 41.1%) were aged 17–29 years. At the time of acute COVID-19 infection, 194 (80.5%) responders were classified as mild, 30 (12.4%) as moderate, 11 (4.6%) as asymptomatic, and 6 (2.5%) as severe; however, none were classified as critical. Hospitalization sites during isolation were 132 (54.8%), therapeutic living centers (isolation facilities for asymptomatic COVID-19 patients) were 106 (44%), and self-isolation was (1.2%). Among those whose symptoms lasted up to 12 months, 98 (77.2%) were women; however, 66 (57.9%) women responded that they did not have symptoms that lasted up to 12 months (Table 1). No differences in sex distribution were identified in subgroup analyses between the participant aged < 50 years and those aged ≥50 years in the group with persistent symptoms (P=0.342) (Additional file 1: Table S1). Those who responded had symptoms that persisted for more than 12 months and a higher median age of 41 years, as compared to the asymptomatic median age of 30 (P=0.017); however, no statistically significant difference was identified in the age groups classified according to 10-year intervals (P=0.181). Persistent symptoms for more than 12 months were more in those classified as moderate or higher disease severity during acute COVID-19 infection (P=0.018) (Table 1). Seventy-nine (32.8%, 79/241) responders reported that they had a newly diagnosed disease due to COVID-19 infection. Twelve (5.0%, 12/241) responders were newly diagnosed with high blood pressure, 8 (3.3%, 8/241) responders were diagnosed with diabetes, and 4 (1.7%, 4/241) responders were newly diagnosed with liver disease.

Eighty-three (34.4%, 83/241) responders reported the worsening of underlying diseases. Seven (2.9%, 7/241) responders reported that their high blood pressure worsened and 8 (3.3%, 8/241) responders reported that their diabetes worsened. Twelve (5.0%,
12/241) responders were undergoing outpatient treatment after 12 months from symptom onset or diagnosis. Among these 12 responders, 4 (5.7%, 4/70) were aged over 50 years and 8 (4.7%, 8/171) were aged under 50 years, which implied that the proportion of responders aged ≥ 50 years who were treated in outpatient clinics for COVID-19-related persistent symptoms was higher than those aged < 50 years.

Table 1 Clinical characteristics of 241 respondents according to the presence of persistent symptoms or signs identified after 12 months of recovery from acute COVID-19 infection

| Characteristics                                        | Total (N = 241) | No symptom (N = 114) | Symptom (N = 127) | P value |
|--------------------------------------------------------|-----------------|----------------------|-------------------|---------|
| Days from COVID-19 diagnosis to survey, median [IQR]    | 454.0 [451.0–458.0] | 453.0 [450.0–456.0] | 455.0 [452.0–458.0] | 0.009   |
| Days from COVID-19-related symptom onset to diagnosis, | 1.0 [0.0–4.0] | 0.0 [0.0–3.0] | 1.0 [0.0–5.0] | 0.015   |
| Sex                                                    |                 |                      |                   | 0.002   |
| Male                                                   | 77 (32.0%) | 48 (42.1%) | 29 (22.8%) |          |
| Female                                                 | 164 (68.0%) | 66 (57.9%) | 98 (77.2%) |          |
| Age, median [IQR] (years)                              | 37.0 [26.0–51.0] | 30.0 [25.0–49.0] | 41.0 [26.0–52.5] | 0.017   |
| Age distribution (years)                               |                 |                      |                   | 0.181   |
| 17–29                                                  | 99 (41.1%) | 55 (48.2%) | 44 (34.6%) |          |
| 30–39                                                  | 31 (12.9%) | 15 (13.2%) | 16 (12.6%) |          |
| 40–49                                                  | 41 (17.0%) | 17 (14.9%) | 24 (18.9%) |          |
| 50–59                                                  | 50 (20.7%) | 21 (18.4%) | 29 (22.8%) |          |
| 60–70                                                  | 20 (8.3%) | 6 (5.3%) | 14 (11.0%) |          |
| Age (years)                                            |                 |                      |                   | 0.111   |
| < 50                                                   | 171 (71.0%) | 87 (76.3%) | 84 (66.1%) |          |
| ≥ 50                                                   | 70 (29.0%) | 27 (23.7%) | 43 (33.9%) |          |
| Disease severity                                       |                 |                      |                   | <0.001  |
| Asymptomatic                                           | 11 (4.6%) | 11 (9.6%) | 0 (0.0%) |          |
| Mid                                                    | 194 (80.5%) | 93 (81.6%) | 101 (79.5%) |          |
| Moderate                                                | 30 (12.4%) | 10 (8.8%) | 20 (15.7%) |          |
| Severe                                                 | 6 (2.5%) | 0 (0.0%) | 6 (4.7%) |          |
| Critical                                                | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |          |
| Disease severity                                       |                 |                      |                   | 0.018   |
| < Moderate                                              | 205 (85.1%) | 104 (91.2%) | 101 (79.5%) |          |
| ≥ Moderate                                              | 36 (14.9%) | 10 (8.8%) | 26 (20.5%) |          |
| Isolation period, median [IQR]                          | 27.0 [21.0–37.0] | 27.0 [20.0–36.0] | 27.0 [22.0–38.0] | 0.444   |
| Isolation period                                       |                 |                      |                   | 0.633   |
| < 3 weeks                                              | 59 (24.5%) | 30 (26.3%) | 29 (22.8%) |          |
| ≥ 3 weeks                                              | 182 (75.5%) | 84 (73.7%) | 98 (77.2%) |          |
| Isolated place*                                         |                 |                      |                   | 1.000   |
| Secondary or Tertiary hospital                         | 132 (54.8%) | 49 (43.0%) | 83 (65.4%) |          |
| Therapy living center                                  | 106 (44.0%) | 63 (55.3%) | 43 (33.9%) |          |
| Self-home isolation                                    | 3 (1.2%) | 2 (1.8%) | 1 (0.8%) |          |
| Underlying psychiatric disease                         |                 |                      |                   | 1.000   |
| No                                                     | 249 (99.2%) | 113 (99.1%) | 126 (99.2%) |          |
| Yes                                                    | 2 (0.8%) | 1 (0.9%) | 1 (0.8%) |          |

*Isolated place: The place where patients were quarantined after being diagnosed with COVID-19 for the first time

*a Panic disorder

*b Major depressive disorder, panic disorder
Characteristics of persistent symptoms and quality of life assessment

The most frequent symptom that lasted up to 12 months was concentration difficulty, which was seen in 54 (22.4%) responders, followed by cognitive dysfunction seen in 51 (21.2%) responders, amnesia in 48 (19.9%) responders, depression in 43 (17.8%) responders, and fatigue and anxiety in 39 (16.2%) responders (Fig. 1). Among the symptoms identified during isolation following acute COVID-19 infection, constitutional symptoms, including fever and myalgia, account for the largest number of cases, with a sharp decrease in the number of respondents complaining over time. However, psychiatric symptoms, such as anxiety, depression, insomnia, social phobia, cognitive dysfunction, and amnesia, continued to increase among the number of respondents.

![Fig. 1 Distribution of 45 persistent symptoms or signs over 12 months after acute COVID-19 infection](image-url)
after 1 month from the onset of COVID-19-related symptoms or diagnosis. After 1–6 months, 6–12 months, and 12 months from the onset of COVID-19-related symptoms or diagnosis, it was confirmed that the persistent symptoms continued to decrease over time. However, unlike other symptoms, psychiatric symptoms were found to be relatively slow to resolve, lasting more than 12 months (Fig. 2). The nine major symptoms of interest (fatigue, anxiety, depression, insomnia, concentration difficulties, cognitive dysfunction, amnesia, anosmia, and ageusia) improved over time. Among the psychiatric symptoms, the percentage of psychiatric improvement was low, especially up to 12 months after COVID-19 diagnosis, as compared to other psychiatric-related symptoms (Fig. 3). EQ5D test for assessment of quality of life confirmed that 19 (7.9%) responders had mobility problems. In total, 3 (1.2%) responders had mobility problems with self-care, 37 (15.4%) with their daily activities, 53 (22.0%) with their pain/discomfort, and 98 (40.7%) responders with their anxiety/depression (Fig. 4). Among the COVID-19-related persistent symptoms, psychiatric problems had a greater impact on quality of life than any other symptoms (Fig. 5).

The nine major symptoms of interest (fatigue, anxiety, depression, insomnia, concentration difficulties, cognitive dysfunction, amnesia, anosmia, and ageusia) were analyzed according to age. Compared with the total number of respondents of each age group, respondents aged 50–59 years most frequently presented with signs of depression, concentration difficulties, cognitive dysfunction, and amnesia symptoms 12 months after the COVID-19-related symptom onset or diagnosis (Additional file 2: Fig. S1). The most frequent symptoms of interest by age group were concentration difficulties at 18–49 years, cognitive dysfunction at 50–59 years, and fatigue at ≥60 years (Additional file 3: Fig. S2). The most frequent symptoms of interest according to disease severity during acute COVID-19 infection were concentration difficulties in the mild group; anxiety, concentration difficulties, and cognitive dysfunction in the moderate group; and depression, concentration difficulties, and amnesia in the severe group (Additional file 4: Fig. S3). The most frequent symptoms of interest by sex were concentration difficulties and cognitive dysfunction in both women and men, but more frequent in women than in men (Additional file 5: Fig. S4). We divided the study responders into age groups (<50 and ≥50 years), which did not show any difference in the main symptom distribution that lasted up to 12 months after the symptom onset or diagnosis. We found that fatigue, cognitive dysfunction, and amnesia were statistically more frequent among responders aged ≥50 years than those aged <50 years. In particular, cognitive dysfunction showed a difference in the frequency of 14.4% between the two groups (P = 0.020) (Additional file 6: Fig. S5). Based on the disease severity at the time of diagnosis, we divided the responders into < moderate and ≥ moderate group to determine the distribution of major symptoms of interest that lasted...
up to 12 months and found that the frequency of persistent psychiatric symptoms was higher in the \( \geq \) moderate group than in the \(< \) moderate group. However, only anxiety symptom was significantly higher in \( \geq \) moderate group than in \(< \) moderate group \((P=0.022)\). Anosmia and ageusia continued to have a higher frequency in the \(< \) moderate group than in the \( \geq \) moderate groups, but no statistical difference was found \((P=0.580\) and
In the main sex-specific distribution of symptoms of interest, women were found to have a higher frequency of prolonged psychiatric problems than men; however, intergroup statistically significant difference was only in terms of amnesia ($P = 0.018$) (Additional file 8: Fig. S7).

Factors associated with the prevalence of persistent symptoms after 12 months of recovery from acute COVID-19 infection

According to the univariate and multivariate logistic regression analysis conducted to identify factors related to prevalence of persistent symptoms after 12 months of recovery from acute COVID-19 infection. For depression (OR 2.34 [1.08–5.68], $P = 0.043$), insomnia (OR 2.84 [1.13–8.65], $P = 0.040$), and amnesia (OR 2.97 [1.36–7.24], $P = 0.010$), the female sex was identified as a relevant factor. For cognitive dysfunction (OR 2.19 [1.11–4.29], $P = 0.022$) and amnesia (OR 2.20 [1.12–4.32], $P = 0.021$), age of ≥ 50 years was identified as a relevant factor (Table 2).

Discussion

In the present study, we assessed COVID-19-related persistent symptoms in COVID-19 patients after 12 months of recovery from acute COVID-19 infection. In this online survey, 52.7% of the respondents still had at least one persistent symptom. In addition, 5.0% of the total respondents received constant outpatient treatment for COVID-19-related persistent symptoms. Although the COVID-19 related persistent symptoms improved over time, we found that neurocognitive symptoms persisted for 12 months after acute COVID-19 infection. Older age (≥ 50 years), female sex, and disease severity (≥ moderate) were identified as risk factors for neuropsychiatric persistent symptoms.

COVID-19-related persistent symptoms showed broad heterogeneity in terms of frequency and type depending on the time of assessment [14–16]. In a longitudinal prospective study with mild or asymptomatic COVID-19, 34.8% experienced at least one symptom (anosmia, ageusia, fatigue, or shortness of breath) at 7 months [6]. Persistent complications in mild COVID-19 patients decreased over time but were still reported in 28% of the study participants after 12 months of recovery from acute COVID-19 infection [3]. A previous study also showed that 56.9% recovered patients, including the 84.4% patients with moderate or higher disease severity still experienced COVID-19-related persistent symptoms 12 months after acute infection [2]. Patients with higher disease severity had a high rate of persistent symptoms that lasted up to 12 months, but these frequencies may vary depending on the symptoms included in the long-term complication study. Our study involved 194 (80.5%) responders with mild disease severity and revealed that 52.7% patients still complained of COVID-19-related persistent symptoms and the persistency rate was higher than the previous study on mild COVID-19 patients. This frequency difference may be because our study included more diverse types of persistent symptoms.

Of the diverse persistent symptoms, the main symptoms identified in our study were difficulty in concentration, cognitive dysfunction, amnesia, depression, fatigue, and anxiety, which are similar to those reported in previous studies [3, 13]. The possible mechanism of presenting neuropsychological symptoms was explained by a disruption in the blood–brain barrier caused by inflammation, leading to increased permeation of cytokines into the central nervous system. Neuroinflammation from microglial activation and oxidative stress might contribute to delirium in the short term and severe cognitive and functional decline in the long term [17]. Our study demonstrated that neurological symptoms could persist at higher rates for longer periods of time than other symptoms. A study has reported that neurologic manifestations, including cognitive dysfunction induced by COVID-19 infection were the major symptoms in non-hospitalized population [18]. Our study also showed that patients who have recovered from mild COVID-19 can present neurological complications. The strength of our study is that we revealed that mild COVID-19 illness can result in prolonged illness and persistent neurological symptoms, even in young adults and persons with no underlying medical diseases.

We confirmed that the frequencies of neuropsychiatric persistent symptoms were somewhat different even between countries and races. An online survey study...
conducted in the United Kingdom and United States 7 months after COVID-19 infection showed that 85.1% of respondents experienced brain fog; moreover, cognitive dysfunction and memory impairments were reported in 72.8% of respondents [11]. Our study, in which all participants were of the Asian ethnicity, showed that 47.7% of respondents experienced concentration difficulty, cognitive dysfunction, amnesia, or brain fog after 12 months of recovery from acute COVID-19 infection. It has been confirmed that the number of respondents with long-lasting symptoms in Asian races is relatively lower than in that in other races. This result might be explained by the possibility of coronavirus resistance gene mutation occurring among East Asians as a result of long-term co-evolution of the virus and host [19, 20].

Among the other important neurological symptoms, anosmia has been frequently reported. Anosmia usually shows spontaneous improvement over a period of 2–3 weeks. However, some COVID-19 patients remain anosmic for a longer period [21]. Previous studies have reported that anosmia and ageusia were presented in 27.3% patients with a median age of 72 years after 12 months of recovery from COVID-19 infection [2], whereas 96.1% patients had objectively recovered from the anosmia symptom after 12 months in another study that comprised of women and patients younger than < 50 years [22]. In our study, which was mainly composed of younger patients with a median age of 37 years, anosmia was present in 6.2% of the total respondents. Our result supported the fact that full olfactory recovery is positively associated with younger age [23].

Table 2 Univariate and multivariate logistic regression analysis for the factors associated with persistent symptoms or signs after 12 months of recovery from COVID-19

| Persistent symptoms or signs | Factors | Univariate OR 95% CI | P value | Multivariate OR 95% CI | P value |
|-----------------------------|---------|----------------------|---------|------------------------|---------|
| Fatigue                     | ≥ Moderate severity  | 2.33 (0.98–5.24)     | 0.045   | 2.02 (0.82–4.72)       | 0.114   |
|                            | ≥ 50 years old       | 2.17 (1.06–4.40)     | 0.031   | 2.00 (0.94–4.18)       | 0.066   |
|                            | Female sex           | 2.01 (0.91–4.91)     | 0.099   | 2.22 (0.99–5.53)       | 0.066   |
| Anxiety                     | ≥ Moderate severity  | 2.78 (1.20–6.19)     | 0.014   | 2.89 (1.24–6.49)       | 0.111   |
|                            | ≥ 50 years old       | 1.10 (0.51–2.28)     | 0.796   | –                      | –       |
|                            | Female sex           | 1.69 (0.79–3.97)     | 0.198   | 1.78 (0.82–4.24)       | 0.163   |
| Depression                  | ≥ Moderate severity  | 1.13 (0.43–2.67)     | 0.786   | –                      | –       |
|                            | ≥ 50 years old       | 1.22 (0.59–2.45)     | 0.576   | –                      | –       |
|                            | Female sex           | 2.34 (1.08–5.68)     | 0.043   | 2.34 (1.08–5.68)       | 0.043   |
| Insomnia                    | ≥ Moderate severity  | 1.74 (0.65–4.21)     | 0.242   | –                      | –       |
|                            | ≥ 50 years old       | 1.33 (0.59–2.88)     | 0.477   | –                      | –       |
|                            | Female sex           | 2.84 (1.13–8.65)     | 0.040   | 2.84 (1.13–8.65)       | 0.040   |
| Concentration difficulty    | ≥ Moderate severity  | 2.76 (1.03–4.79)     | 0.036   | 2.06 (0.91–4.52)       | 0.076   |
|                            | ≥ 50 years old       | 1.79 (0.94–3.38)     | 0.073   | 1.63 (0.83–3.17)       | 0.150   |
|                            | Female sex           | 1.86 (0.94–3.93)     | 0.085   | 2.01 (1.00–4.13)       | 0.058   |
| Cognitive dysfunction       | ≥ Moderate severity  | 1.81 (0.80–3.92)     | 0.139   | 1.51 (0.64–3.41)       | 0.328   |
|                            | ≥ 50 years old       | 2.24 (1.17–4.27)     | 0.014   | 2.19 (1.11–4.29)       | 0.022   |
|                            | Female sex           | 1.94 (0.96–4.19)     | 0.077   | 2.11 (1.03–4.64)       | 0.051   |
| Amnesia                     | ≥ Moderate severity  | 1.42 (0.59–3.16)     | 0.409   | –                      | –       |
|                            | ≥ 50 years old       | 2.04 (1.05–3.94)     | 0.033   | 2.20 (1.12–4.32)       | 0.021   |
|                            | Female sex           | 2.78 (1.29–6.71)     | 0.014   | 2.97 (1.36–7.24)       | 0.010   |
| Anosmia                     | ≥ Moderate severity  | 0.39 (0.02–2.04)     | 0.370   | –                      | –       |
|                            | ≥ 50 years old       | 2.26 (0.76–6.56)     | 0.129   | 2.26 (0.76–6.56)       | 0.129   |
|                            | Female sex           | 1.31 (0.43–4.86)     | 0.651   | –                      | –       |
| Ageusia                     | ≥ Moderate severity  | 0.81 (0.04–4.74)     | 0.844   | –                      | –       |
|                            | ≥ 50 years old       | 4.31 (1.03–14.19)    | 0.050   | 4.31 (1.03–14.19)      | 0.050   |
|                            | Female sex           | 0.46 (0.11–1.98)     | 0.276   | –                      | –       |

OR odds ratio; CI confidence interval.
usual health after acute COVID-19 infection. Therefore, this suggested that convalescence can be prolonged even in young adults without chronic medical conditions, and thereby potentially lead to prolonged absence from work, studies, or other activities [25]. The findings of our study showed that 15.4% of the respondents had problems with their daily activities and 40.7% respondents had problems with their anxiety/depression according to the EQ5D instrument for measuring quality of life until 12 months after acute COVID-19 infection.

Patients who had experienced severe COVID-19 had the largest decline in health-related quality of life [26]. Prevention of aggravating COVID-19 with vaccination might be an effective measure to prevent long-term functional decline.

It is unclear why some patients experience long-term symptoms after COVID-19. Potential causes for different outcomes of infection are viral load as well as host-dependent factors, such as genetic susceptibility or induction of anti-inflammatory cells [13]. Increasing age, female sex, disease severity, and body mass index were known as attributes and predictors of persistent COVID-19 infection [27, 28]. A previous study conducted 10 months after the participating patients (median age, 37.8 years) had recovered from an acute COVID-19 infection, similar to our study, showed that older age was associated with greater risk of symptom persistence [29]. Our study demonstrated that factors effecting persistent neuropsychological symptoms after 12 months of recovery from acute COVID-19 infection were associated with age ≥ 50 years and the predominance of women with persistent COVID symptoms, as seen in previous studies [13, 27]. A previous study showed that the presence of post-acute COVID-19 symptoms was more frequently associated with the female sex at 7 months post-COVID-19 infection and that the female sex was associated with depressive symptoms and poor sleep quality, but not with anxiety levels [30]. Our study also showed similar results that persistent symptoms of depression and insomnia were associated with the female sex, but not with anxiety after 12 months of recovery from COVID-19 infection. This study showed that women may be more vulnerable to the impact of sustained neuropsychological persistent symptoms than men. A previous study showed that symptomatic COVID-19 disease with moderate severity, compared with mild severity, was a predictor of persistent COVID-19-like symptoms after discharge [28]. In our study, among the major neurological symptoms, anxiety was identified to be associated with moderate or higher disease severity. Proper targeted interventions can be developed to identify the characteristics of patient groups that are at greater risks of developing long-term persistent neuropsychological symptoms. Early recognition of long-term post-COVID effects and associated risk factors will facilitate diagnosis and multidisciplinary strategies for these patients.

A previous study showed the onset of diabetes and worsening of glycemic control in 1.3% and 10.1% of patients, respectively [2]. The role of SARS-CoV-2 in accelerating type-2 diabetes by binding angiotensin-converting enzyme 2 receptor on endothelial cells and pericytes of islet microvasculature and pancreatic islet cells, thereby resulting in a local cytokine storm that leads to B-cell dysfunction and apoptosis, has been described [31]. Our study evaluated the onset and worsening of underlying diseases in recovered COVID-19 patients. In this study, which includes more young respondents than previous studies, new onset of diabetes or worsening glucose control was reported in 3.3% of responders. It is suggested that follow-up observations of diabetes may be necessary in recovered COVID-19 patients.

This study has certain limitations. First, since this study was an online survey study, information on persistent symptoms was reported directly by respondents and was not based on an objective evaluation. Second, older patients who found it relatively difficult to participate in the survey were excluded from the study. As a result, this study included most of the young people and those who were able to participate in the online survey by themselves. Therefore, further research of long-term persistent symptoms on patients with severe sequelae or in the elderly population is required. Third, we cannot exclude the contribution of the influence of the long pandemic situation and consecutive psychological impact on the psychological long-term persistent symptoms. Fourth, we were unable to evaluate a control group without COVID-19. Therefore, to accurately evaluate the effects of COVID-19 infection on newly diagnosed diseases, including diabetes, comparative studies with these controls are warranted in the future.

Despite these limitations, our results highlight the need to enhance the preparedness and competence of healthcare professionals in the detection and management of the psychological persistent symptoms related to the current COVID-19 pandemic. Moreover, our study showed the importance of future researches on persistent symptoms after COVID-19 infection in vaccinated population, since neurological symptoms can persist until 12 months after recovery from COVID-19 infection, even in patients with mild COVID-19. Whether SARS-CoV-2 infection can promote the development of brain degenerative diseases decades later have not been identified, though it is theoretically possible [32]. Most of the clinical studies about long-term persistent symptoms after COVID-19 infection were conducted in unvaccinated populations. The long-term persistent symptom risk for the fully
vaccinated who get infected after vaccination has not been investigated. Future research is needed to clarify whether COVID-19 vaccination can reduce the incidence of long-term persistent symptoms after COVID-19 infection.

Conclusions

Long-term persistent symptoms were manifested in various forms. We found that neurocognitive symptoms can persist 12 months after recovery from COVID-19, thereby reducing quality of life. Continuous careful observation related to symptom improvement and multidisciplinary integrated research in recovered COVID-19 patients are needed.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07062-6.

Additional file 1: Table S1. Sex and age distribution of 241 respondents after 12 months from acute COVID-19 infection

Additional file 2: Figure S1. Nine major persistent symptoms of concern according to age group distribution.

Additional file 3: Figure S2. Nine major persistent symptoms of concern based on the sex

Additional file 4: Figure S3. Nine major persistent symptoms of concern based on the disease severity groups.

Additional file 5: Figure S4. Nine major persistent symptoms of concern based on sex

Additional file 6: Figure S5. Nine major persistent symptoms of concern based on < 50 and ≥ 50 years age groups

Additional file 7: Figure S6. Nine major persistent symptoms of concern based on < moderate or ≥ moderate disease severity groups

Acknowledgements

Not applicable.

Author contributions

Conceptualization: YJK, SWK. Formal analysis and data curation: YJK, SWK. Validation: YJK, KTK, HHC, SWK. Investigation: YJK, BNH, SHB, SYH, KTK, HHC, SWK. Supervision: SWK. Writing—original draft: YJK. Writing—review & editing: SHB, BNH, SYH, KTK, HHC, SWK. Approval of final manuscript: All authors. All authors read and approved the final manuscript.

Funding

The present study was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (Fund Code 2020-ERS334-00, 2021-ER1901-00).

Availability of data and materials

The datasets used in the present study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was reviewed and approved by the Institutional Review Board of Kyungpook National University Hospital (Approval No.: 2021-02-003). All respondents provided digital informed consents before the questionnaire was administered.

Consent for publication

Not applicable.

Competing interests

The authors declare no potential conflicts of interest.

Received: 7 September 2021 Accepted: 13 January 2022 Published online: 27 January 2022

References

1. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. Front Med. 2021. https://doi.org/10.3389/fmed.2021.653516.

2. Maestre-Muniz MM, Arias A, Mata-Vazquez E, Martin-Toledano M, Lopez-Larramona G, Ruiz-Chicote AM, Nieto-Sandoval B, Lucendo AJ. Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge. J Clin Med. 2021;10(13):2945.

3. Rank A, Tzortzini A, Kling E, Schmid C, Claus R, Loll E, Burger R, Rommele C, Dhillon C, Muller K, et al. One year after mild COVID-19: the majority of patients maintain specific immunity, but one in four still suffer from long-term symptoms. J Clin Med. 2021;10(15):3304.

4. Kim Y, Kim S-W, Chang H-H, Kwon KT, Bae S, Hwang S. Significance and associated factors of long-term sequelae in patients after acute COVID-19 infection in Korea. Infect Chemother. 2021;53:463.

5. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O’Connor L, Leavy D, O’Brien K, Dowds J, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15(11):e0240784.

6. Augustin M, Schommers P, Stecher M, Devald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:101012.

7. Nuzzo D, Vasto S, Scalisi L, Cottone S, Cambula G, Rizzo M, Giacomazza D, Picone P. Post-acute COVID-19 neurological syndrome: a new medical challenge. J Clin Med. 2021;10(9):1947.

8. Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, Lapperre T, Porsberg CM. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39–48.

9. Alnefeesi Y, Siegel A, Lui LMW, Teopiz KM, Ho RCM, Lee Y, Nasri F, Gill H, Lin K, Cao B, et al. Impact of SARS-CoV-2 infection on cognitive function: a systematic review. Front Psychiatry. 2020;11:621773.

10. Daroische R, Hemminghuyt MS, Eilersen TH, Breitve MH, Chwiszczuk LJ. Cognitive impairment after COVID-19—a review on objective test data. Front Neurol. 2021;12:699562.

11. Davis HE, Assaf GO, McCorkell L, Wei H, Low RJ, Reem Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.

12. Hampshire A, Trender W, Chamberlain SR, Jolly AE, Grant JE, Patrick F, Madbuko N, Williams SC, Barnby JM, Hellyer Y, et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044.

13. Seessle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, Muller U. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciaa611.

14. Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, Stamatelopoulos K, Terpos E, Kotonidou A, Hagberg CA,
et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect. 2021;83(1):1–16.

15. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–32.

16. Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, Ma W, Wang X. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020;35(47):e418.

17. Baker HA, Safavynia SA, Evered LA. The “third wave”: impending cognitive and functional decline in COVID-19 survivors. Br J Anaesth. 2021;126(1):44–7.

18. Ding H, Yin S, Cheng Y, Cai Y, Huang W, Deng W. Neurologic manifestations of nonhospitalized patients with COVID-19 in Wuhan, China. MedComm (Beijing). 2020. https://doi.org/10.1002/mco.100210.

19. Yamamoto N, Bauer G. Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: four hypotheses for possible explanation. Med Hypotheses. 2020;144:10160.

20. Souilmi Y, Lauterbur ME, Tobler R, Huber CD, Johar AS, Moradi SV, Johnston WA, Krogaan NJ, Alexandrov K, Enard D. An ancient viral epidemic involving host coronavirus interacting genes more than 20,000 years ago in East Asia. Curr Biol. 2021;31(16):3504–14.

21. Wostyn P. Anosmia as a predictor for post-COVID-19 fatigue syndrome. Lancet Reg Health Europe. 2021;7:100162–100162.

22..restart et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect. 2021;83(1):1–16.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.